INTRODUCTION
The cyclic AMP-independent stimulation of glycogenolysis in liver by ac-adrenergic agonists, vasopressin and angiotensin is mediated by Ca2+ acting on phosphorylase b kinase, which will then activate glycogen phosphorylase. Current evidence suggests a mobilization of Ca2+ from the endoplasmic reticulum triggered by inositol trisphosphate generated by hormone-initiated hydrolysis of phosphatidylinositol 4,5-bisphosphate in the plasma membrane [see Williamson et al. (1985) for a review]. Electrical stimulation of the sympathetic innervation of the liver also results in a cyclic AMP-independent glycogenolysis, which has been ascribed to the release of noradrenaline acting on az-adrenoreceptors [see De Wulf & Carton (1981) for a review]. Since in a number of tissues ATP is a co-transmitter in the sympathetic nerve terminals (Burnstock, 1981) , the question arises as to the possibility of a Ca2+-mediated purinergic control of liver glycogenolysis. At least at high concentrations, exogenous ATP reproduces several effects of the Ca2+-dependent glycogenolytic hormones, such as glucose production at 0.1 mM (De Witt & Putney, 1983) , Ca2+ redistribution at 0.3-0.5 mM (Krell et al., 1983) and 0.8 mm (Bellomo et al., 1984) , phosphorylase activation at 0.8 mM (Bellomo et al., 1984) , hydrolysis of phosphatidylinositol 4,5-bisphosphate at 0.1 mM (Creba et al., 1983) and increased inositol trisphosphate at 0.1 mM (Charest et al., 1985) . In the present paper, we show that ATP acts at much lower concentrations and present strong evidence for a common mode of action for ATP and the Ca2+-dependent glycogenolytic hormones.
EXPERIMENTAL
We used male Wistar-strain albino rats (200-250 g body wt.) that were fed ad libitum. Preparation, incubation and sampling of liver cells for the assay of phosphorylase a and the measurement of cyclic AMP were done as described by Keppens & De Wulf (1984) . ATP, ADP, AMP and adenosine were from Sigma Chemical Co. The origin of the other chemicals has been given previously (Keppens & De Wulf, 1984) .
RESULTS AND DISCUSSION Fig. l(a) shows the transient nature of phosphorylase activation after treatment of hepatocytes with different concentrations of ATP. Maximal activation is obtained within 15 s and is followed by a marked decline, most probably due to the rapid hydrolysis of the nucleotide by an ecto-ATPase ofthe cells (see Krell et al., 1983) . Indeed, a second addition of ATP causes identical activation patterns (results not shown). In contrast, the addition of adenosine results in a completely different time-dependent activation of phosphorylase ( Fig. lb) , which is characterized by a lag period of about 10 s. ADP and AMP produce activation patterns similar to those of ATP and adenosine respectively (results not shown). We have not observed any interference with possible contaminants of commercial ATP preparations such as aluminium (Womack & Colowick, 1979) and vanadate (Cantley e al., 1977) . Dose-response curves (Fig. 2) yield the following Ka values: 5 x 10-' M for ATP, 2 x 10-6 M for ADP and about 5 x 10-5 M for AMP and adenosine. This order of potency indicates that ATP interacts with the P2-purinergic receptors, according to the terminology of Burnstock (1981) . This conclusion is confirmed by the lack of any glycogenolytic effect of ATP with cells depleted of Ca2+ by pretreatment with EGTA and by the absence of any effect on cyclic AMP concentrations up to 50 1tM-ATP (results not shown). The glycogenolytic ability of ATP is unlikely to be due to a kinase-initiated sequence of events, since the omission of Mg2+ from the incubation medium was without effect. ATP can thus be considered as being a cyclic AMP-independent Ca2+-dependent glycogenolytic agonist.
Additional evidence points to a common mode of action for ATP and the other Ca2+-dependent agonists.
First, vasopressin and the ac-adrenergic agonists have been shown to induce a heterologous desensitization of the liver glycogenolytic response towards the Ca2+-dependent hormones, which implies that they all share a common mode of action (Breant et al., 1981) . We show in Fig. 3 that vasopressin also decreases the glycogenolytic effect of ATP, with the same dose-dependency as its own glycogenolytic ability. Similar results have been obtained with the al-agonist phenylephrine as the desensitizing agent (results not shown) [owing to its rapid hydrolysis, ATP cannot be employed as a desensitizing agent, as we (Keppens & De Wulf, 1982) have shown that continuous presence of the agonist is mandatory to maintain the desensitized state]. These data strongly suggest that ATP uses the same effector system(s) as the Ca2+-mediated hormones. Secondly, the Ca2+-dependent hormones are able to decrease cyclic AMP in hepatocytes incubated with glucagon [see Keppens & De Wulf (1984) for references]. Fig. 4 illustrates this ability of ATP whether added together with glucagon or 2 min later. Thirdly, we (Keppens & De Wulf, 1984) have attributed this cyclic AMP-decreasing effect by angotensin and vasopressin to an enhanced phosphodiesterase activity, since it is lost in the presence of several phosphodiesterase inhibitors. Similarly, in three independent experiments 3-isobutyll-methylxanthine (50 /SM) prevented 10 #M-ATP from lowering the glucagon-induced cyclic AMP concentrations.
CONCLUSIONS Two conclusions can be drawn from our data. First, liver seems to possess purinergic receptors of the P2-subclass (terminology of Burnstock, 1981) . On release of ATP by the sympathetic nerve terminals, these could, in conjunction with noradrenaline, initiate a Ca2+-dependent glycogen breakdown. Interestingly, the Ka value for ATP (5 x 10-7 M; the present paper) compares favourably with that for noradrenaline (3 x 10-7 M; Breant et al., 1981) . Secondly, ATP shares a common mode of action with the cyclic AMP-independent Ca2+-dependent glycogenolytic hormones angiotensin, vasopressin and al-agonists. This conclusion is substantiated by (1) their requirement for Ca2 , (2) their inability to increase cyclic AMP, (3) their ability to undergo a heterologous desensitization by vasopressin and phenylephrine (an oc1-agonist), (4) their ability to decrease cyclic AMP in hepatocytes challenged with glucagon, most probably mediated by an enhanced phosphodiesterase activity.
